More than one in 10 Americans suffer from migraine headaches, and the vast majority of patients report that the pain prevents them from working. Biohaven Pharmaceuticals, a New Haven based startup, aims to change that.
The clinical stage research company was founded in 2013, went public in 2017, and expects to begin marketing its first commercial offering in 2020, a new drug for acute migraine sufferers.